Biogen Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $9.9B+2.7% YoYTTM through 31 Mar 2026
Net Income $1.4B-15.9% YoYTTM through 31 Mar 2026
Free Cash Flow $2.4BTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| EBITDA Margin | 24.4% |
| Operating Margin | 16.3% |
| Net Margin | 13.8% |
Returns
7.4%ROE
4.7%ROA
6.4%ROIC
Balance Sheet Health
Debt / Equity0.34x
Current Ratio3.06x
Net Debt$2.9B
Cash & Equivalents$3.4B
Quality Metrics
Altman Z-Score3.61
Piotroski F-Score6 / 9
FCF Margin24.4%
Rule of 4029.4
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $9.9B
Diluted EPS$9.30TTMFY2025: $8.79
Dividend
No dividend
Capital Allocation
Capex Intensity1.7%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Biopharmaceutical Operations | $9.9B | +2.2% | View detailsTotal revenue is expected to decline by a mid-single digit percentage for 2026 as compared to 2025 due to further generic erosion in multiple sclerosis products. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.